News
- Author:
- Neil Osterweil
Publish date: April 24, 2019
Long-term follow-up of women with early, HER2-positive breast cancer showed similar efficacy and safety for subcutaneous or intravenous trastuzumab...
News
- Author:
- Neil Osterweil
Publish date: April 23, 2019
Salvage stem cell transplant in patients with multiple myeloma was linked to short-term, but not long-term, declines in quality of life, compared w...
News
- Author:
- Neil Osterweil
Publish date: April 17, 2019
Patients who could not undergo transplants had high rates of complete responses to radioimmunotherapy consolidation following induction chemotherap...
News
- Author:
- Neil Osterweil
Publish date: April 16, 2019
ATLANTA – Combining the investigational MET inhibitor savolitinib to osimertinib was associated with responses in NSCLC resistant to EGFR-targeted ...
Video
- Author:
- Neil Osterweil
Publish date: April 12, 2019
Patients with acute myeloid leukemia and FLT3-activating mutations are at increased risk for early relapse and poor overall survival.
News
- Author:
- Neil Osterweil
Publish date: April 10, 2019
ATLANTA – About one-third of patients with heavily pretreated non–small cell lung cancer had responses to osimertinib and selumetinib.
News
- Author:
- Neil Osterweil
Publish date: April 5, 2019
ATLANTA – A teenage girl with advanced osteosarcoma has had a durable complete remission after receiving CAR T cells targeted to HER2.
Video
- Author:
- Neil Osterweil
Publish date: April 2, 2019
ATLANTA – Investigators are treating patients with advanced pancreatic cancer and homologous recombination deficiencies with a novel strategy of in...
Video
- Author:
- Neil Osterweil
Publish date: April 2, 2019
ATLANTA - Dr. Yadav Sapkota of St. Jude Children's Research Hospital discusses the identification of a genetic variant that is strongly associated ...
Video
- Author:
- Neil Osterweil
Publish date: April 1, 2019
ATLANTA – Dr. Lecia Sequist discusses early results from the TATTON trial, which is evaluating osimertinib plus savol...
Video
- Author:
- Neil Osterweil
Publish date: April 1, 2019
ATLANTA – Although HER2 expression in osteosarcoma and rhabomyosarcoma is too low for HER2-targeted therapies such as...
News
- Author:
- Neil Osterweil
Publish date: March 27, 2019
Women with no prior tamoxifen exposure benefited most from the combination, compared with those receiving anastrozole alone.
News
- Author:
- Neil Osterweil
Publish date: March 26, 2019
Noninvasive ultra-deep sequencing of cell-free plasma DNA identified driver mutations with results comparable to those of genotyping of biopsied ti...
News
- Author:
- Neil Osterweil
Publish date: March 13, 2019
Patients older than 65 years who were ineligible for induction chemotherapy benefited from the addition of pracinostat to the standard of care trea...
News
- Author:
- Neil Osterweil
Publish date: March 12, 2019
SAN FRANCISCO – A one-two approach to stimulating both innate and adaptive immunity appears to be paying off, suggest early efficacy data from a ph...
